| 40.88 |  +0.29 / +0.71% |
Data as of 4:00pm ET | Day’s Change |
| 40.88 |  0.00 / 0.00% |
Volume: 625.00 |
| FDA Designation for Synageva Candidate - Analyst Blog May 22 / Zacks.com |
| Previous close | 40.59 |
| Today’s open | 40.46 |
| Day’s range | 40.33 - 41.11 |
| Volume | 77,456 |
| Average volume (3 months) | 96,934 |
| Market cap | $1.1B |
| Dividend yield | -- |
| Earnings growth (last year) | +77.86% |
| Earnings growth (this year) | -65.07% |
| Earnings growth (next 5 years) | +36.00% |
| Revenue growth (last year) | +612.51% |
| P/E ratio | NM |
| Price/Sales | 69.89 |
| Price/Book | 4.31 |
| Today’s change | Today’s % change | |
|---|---|---|
| HALOHalozyme Therapeutic... | -0.03 | -0.40% |
| ITMNInterMune Inc | -0.38 | -3.82% |
| IMGNImmunogen Inc | +0.15 | +0.85% |
| MNTAMomenta Pharmaceutic... | +0.08 | +0.60% |
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | -$0.78 |
| Annual revenue (last year) | $15.0M |
| Annual profit (last year) | -$42.9M |
| Net profit margin | -287.21% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Sanj K. Patel |
Chief Financial Officer & Senior Vice President Carsten Boess |
Corporate headquarters Lexington, Massachusetts |
.
